Masimo (NASDAQ:MASI) Announces Quarterly Earnings Results

Masimo (NASDAQ:MASI) posted its quarterly earnings data on Tuesday. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38, Zacks reports. Masimo had a net margin of 3.85% and a return on equity of 14.98%.

Masimo Stock Performance

NASDAQ:MASI traded down $1.18 during trading hours on Tuesday, reaching $169.54. The stock had a trading volume of 687,596 shares, compared to its average volume of 484,055. Masimo has a 12-month low of $101.61 and a 12-month high of $184.51. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a 50 day simple moving average of $172.65 and a 200 day simple moving average of $152.54. The stock has a market cap of $9.08 billion, a P/E ratio of 116.92 and a beta of 1.02.

Analyst Ratings Changes

Several research firms recently weighed in on MASI. Raymond James boosted their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a report on Friday, December 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Wells Fargo & Company boosted their price objective on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler raised their target price on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $191.40.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.